Novo Nordisk (GB:0QIU)

LSE:0QIU

0QIU

Novo Nordisk

RESEARCH TOOLSreports

Novo Nordisk (0QIU) Share Forecast & Price Target

81 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QIU Analyst Ratings

Hold

1 Buy

11 Hold

2 Sell

Based on 14 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr294.54

▲(26.33% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr294.54 with a high forecast of kr380.00 and a low forecast of kr250.00. The average price target represents a 26.33% change from the last price of kr233.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"224":"kr224","461":"kr461","283.25":"kr283.3","342.5":"kr342.5","401.75":"kr401.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":294.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr294.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr250.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[224,283.25,342.5,401.75,461],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,236.505,247.5430769230769,258.5811538461538,269.61923076923074,280.6573076923077,291.6953846153846,302.73346153846154,313.77153846153846,324.80961538461537,335.84769230769234,346.88576923076926,357.92384615384617,368.9619230769231,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,236.505,240.96923076923076,245.43346153846153,249.8976923076923,254.3619230769231,258.82615384615383,263.2903846153846,267.7546153846154,272.2188461538462,276.68307692307695,281.1473076923077,285.6115384615385,290.07576923076925,{"y":294.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,236.505,237.5430769230769,238.58115384615385,239.61923076923077,240.65730769230768,241.69538461538463,242.73346153846154,243.77153846153846,244.80961538461537,245.8476923076923,246.88576923076923,247.92384615384614,248.96192307692309,{"y":250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":460.026,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":412.489,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.855,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":413.513,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.151,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":356.302,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":343.785,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.761,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.134,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":316.03,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":360.612,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.685,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":236.505,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr380.00

Average Price Targetkr294.54

Lowest Price Targetkr250.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Gordon CFA

Barclays

kr270

Hold

15.81%

Upside

Reiterated

04/02/26

Barclays Sticks to Its Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr260→kr263

Hold

12.80%

Upside

Reiterated

03/31/26

Goldman Sachs Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Richard Vosser

J.P. Morgan

kr250

Hold

7.23%

Upside

Reiterated

03/30/26

J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

kr275

Hold

17.95%

Upside

Reiterated

03/26/26

Deutsche Bank Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

kr275→kr270

Hold

15.81%

Upside

Reiterated

03/24/26

Jefferies Remains a Hold on Novo Nordisk (0QIU)

Justin Smith

Bernstein

―

Sell

―

Initiated

03/19/26

Novo Nordisk (0QIU) Receives a New Rating from Bernstein

Rajesh Kumar

HSBC

kr350→kr280

Hold

20.09%

Upside

Reiterated

03/17/26

Novo Nordisk price target lowered to DKK 280 from DKK 350 at HSBCNovo Nordisk price target lowered to DKK 280 from DKK 350 at HSBC

Kerry Holford

Berenberg Bank

kr360→kr300

Buy

28.67%

Upside

Reiterated

03/12/26

Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)

David Evans

Kepler Capital

kr400→kr280

Hold

20.09%

Upside

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at Kepler CheuvreuxNovo Nordisk downgraded to Hold from Buy at Kepler Cheuvreux

Graham Parry

Citi

kr340→kr309

Hold

32.53%

Upside

Reiterated

02/24/26

Novo Nordisk price target lowered to DKK 309 from DKK 340 at CitiNovo Nordisk price target lowered to DKK 309 from DKK 340 at Citi

Matthew Weston

UBS

kr332

Hold

42.40%

Upside

Reiterated

02/23/26

UBS Remains a Hold on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

kr400→kr350

Hold

50.12%

Upside

Reiterated

02/05/26

Novo Nordisk price target lowered to DKK 350 from DKK 400 at BofANovo Nordisk price target lowered to DKK 350 from DKK 400 at BofA

Thibault Boutherin

Morgan Stanley

kr270

Sell

15.81%

Upside

Reiterated

02/04/26

Morgan Stanley Sticks to Its Sell Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr380

Hold

62.99%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and HCA Healthcare (NYSE: HCA)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

11/24/25

DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Gordon CFA

Barclays

kr270

Hold

15.81%

Upside

Reiterated

04/02/26

Barclays Sticks to Its Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr260→kr263

Hold

12.80%

Upside

Reiterated

03/31/26

Goldman Sachs Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Richard Vosser

J.P. Morgan

kr250

Hold

7.23%

Upside

Reiterated

03/30/26

J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

kr275

Hold

17.95%

Upside

Reiterated

03/26/26

Deutsche Bank Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

kr275→kr270

Hold

15.81%

Upside

Reiterated

03/24/26

Jefferies Remains a Hold on Novo Nordisk (0QIU)

Justin Smith

Bernstein

―

Sell

―

Initiated

03/19/26

Novo Nordisk (0QIU) Receives a New Rating from Bernstein

Rajesh Kumar

HSBC

kr350→kr280

Hold

20.09%

Upside

Reiterated

03/17/26

Novo Nordisk price target lowered to DKK 280 from DKK 350 at HSBCNovo Nordisk price target lowered to DKK 280 from DKK 350 at HSBC

Kerry Holford

Berenberg Bank

kr360→kr300

Buy

28.67%

Upside

Reiterated

03/12/26

Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)

David Evans

Kepler Capital

kr400→kr280

Hold

20.09%

Upside

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at Kepler CheuvreuxNovo Nordisk downgraded to Hold from Buy at Kepler Cheuvreux

Graham Parry

Citi

kr340→kr309

Hold

32.53%

Upside

Reiterated

02/24/26

Novo Nordisk price target lowered to DKK 309 from DKK 340 at CitiNovo Nordisk price target lowered to DKK 309 from DKK 340 at Citi

Matthew Weston

UBS

kr332

Hold

42.40%

Upside

Reiterated

02/23/26

UBS Remains a Hold on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

kr400→kr350

Hold

50.12%

Upside

Reiterated

02/05/26

Novo Nordisk price target lowered to DKK 350 from DKK 400 at BofANovo Nordisk price target lowered to DKK 350 from DKK 400 at BofA

Thibault Boutherin

Morgan Stanley

kr270

Sell

15.81%

Upside

Reiterated

02/04/26

Morgan Stanley Sticks to Its Sell Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr380

Hold

62.99%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and HCA Healthcare (NYSE: HCA)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

11/24/25

DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Stocks with the Highest Top Analyst Consensus in the General Sector

xxx

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months

xxx

Success Rate

2/6 ratings generated profit

Average Return

-15.52%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -15.52% per trade.

1 Year

Kerry HolfordBerenberg Bank

Success Rate

1/6 ratings generated profit

Average Return

-21.53%

reiterated a buy rating 28 days ago

Copying Kerry Holford's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -21.53% per trade.

2 Years

xxx

Success Rate

1/6 ratings generated profit

Average Return

-21.53%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -21.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QIU has received 9 Buy Ratings, 29 Hold Ratings, and 3 Sell Ratings. 0QIU average Analyst price target in the past 3 months is 294.54.

Each month's total comprises the sum of three months' worth of ratings.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr5.74 with a range of kr4.71 to kr10.09. The previous quarter’s EPS was kr6.04. 0QIU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.89% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr72.54B with a range of kr67.44B to kr95.49B. The previous quarter’s sales results were kr79.14B. 0QIU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 53.24% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 294.54.

What is GB:0QIU’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 26.33% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Hold, which is based on 1 buy ratings, 11 hold ratings and 2 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 294.54. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr380.00 ,and the lowest forecast is kr250.00. The average share price target represents 26.33% Increase from the current price of kr233.15.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novo Nordisk (0QIU) Share Forecast & Price Target

0QIU Analyst Ratings

0QIU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

0QIU Analyst Recommendation Trends

0QIU Financial Forecast

0QIU Earnings Forecast

0QIU Sales Forecast

0QIU Stock Forecast FAQ

Detailed List of Analyst Forecasts